论文部分内容阅读
目的:探讨肝硬化并发肝源性糖尿病患者的临床治疗方法与效果。方法:选取对入院收治的84例肝硬化合并糖尿病患者作为研究对象,按照治疗方法将患者分为观察组与对照组,每组42例。观察组给予口服恩替卡韦治疗,对照组给予口服阿德福韦酯治疗,两组均治疗48周。同时所有患者均给予糖尿病饮食、控制血糖及综合护肝、降酶等对症支持治疗。对比分析两组治疗前后肝功能、病毒学应答情况及血糖水平。结果:两组治疗后总胆红素(TBil)、直接胆红素(DBil)、丙氨酸转氨酶(ALT)和天冬氨酸转氨酶(AST)水平低于治疗前(P<0.05),白蛋白(Alb)水平高于治疗前(P<0.05)。结论:相比阿德福韦酯,恩替卡韦治疗乙型病毒性肝炎肝硬化合并糖尿病,能明显改善肝功能,增强肝糖原代谢能力,更好的控制血糖,有利于提高患者预后生活质量。
Objective: To explore the clinical treatment of liver cirrhosis complicated with liver-derived diabetes mellitus and its effects. Methods: Eighty-four patients with cirrhosis and diabetes mellitus admitted to hospital were enrolled in this study. Patients were divided into observation group and control group according to the treatment method, with 42 cases in each group. The observation group was treated with oral entecavir, while the control group was given adefovir dipivoxil. Both groups were treated for 48 weeks. At the same time, all patients were given diabetes diet, blood sugar control and comprehensive protection of the liver, reducing enzyme symptomatic and supportive treatment. The liver function, virological response and blood glucose level before and after treatment were compared between the two groups. Results: The levels of total bilirubin (TBil), direct bilirubin, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in the two groups were lower than those before treatment (P <0.05) Alb levels were higher than before treatment (P <0.05). Conclusion: Compared with adefovir dipivoxil, entecavir treatment of hepatitis B cirrhosis with diabetes, can significantly improve liver function, enhance hepatic glycogen metabolism, better control of blood glucose, help to improve the prognosis of patients with quality of life.